Overview

Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
Confirm the efficacy of the brexpiprazole QW formulation versus placebo for acute symptoms of schizophrenia
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Collaborator:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Treatments:
Brexpiprazole